• Enorama Pharma seeks shareholder approval to introduce 9% annual interest on a USD 2.5 million loan from principal shareholder DS Global.
• Interest would accrue from the extraordinary shareholder meeting date; the currently interest-free loan matures December 31, 2027.
• The board plans to recommend continued operations rather than liquidation at the second capital impairment meeting, with equity restored above registered share capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enorama Pharma AB published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.